News

The federal agency recommends using either PCV13 or PCV15 as part of a 4-dose series for pediatric patients between the ages of 2-59 months.

The investigational therapy demonstrated time to first resolution of the five COVID-19 symptoms was significantly reduced in those treated with low dose of medication.

C diff patients live in fear of a recurrence, says gastroenterologist Paul Feuerstadt, MD. RBX2660 has entered the FDA pipeline and looks to end this vicious cycle.

A European panel of experts endorsed the FDA’s recommendations.

Interim data show a bivalent vaccine that contains the Omicron variant may be more effective.

Gonococcal septic polyarthritis is an uncommon manifestation of N gonorrhoeae infection, but has increased by about 40% in recent years.

Uganda’s first Ebola outbreak in a decade raises concern due to its vaccine resistance.

Occult HBV infection is likely to go undetected in under-resourced regions of high HBV endemicity and confound WHO goal to eradicate the viral hepatitis by 2030.

With an all-ready challenging patient population to treat, having a program to get more people into treatment can be helpful in an underserved group.

A fecal microbiota transplant (FMT) trial was halted early due to clear evidence the treatment was superior to placebo.

These vaccines target the wild strain as well as the Omicron BA.4/BA.5 variants.

Among pregnant women coinfected with HIV, a higher hepatitis C viral load increased the likelihood of transmitting HCV to children.

Recent issues surrounding the ADAPT-PO and SURE-2 trials place the spotlight on the difficulties developing oral carbapenem-based antibiotics and case their future into doubt.

Investigators examined all-cause excess mortality and sought to uncouple it from COVID-19 in US states with high vaccination rates.

Similar to HIV, the colonial and postcolonial history is fundamental to the biology of this monkeypox outbreak.

Salmonella becomes more dangerous as antimicrobial resistance grows. Read about its most common manifestations.

Although there are challenges for clinical and infectious disease pharmacists when trying to apply this concept, here are some considerations and strategies to employ stewardship in this setting.

Progress in rapid diagnostic and point-of-care testing propelled by the pandemic can improve timeliness and precision of anti-infective treatment.

However, according to one study the risk of heart inflammation increases with age and amplifies in patients with hepatitis C (HCV) compared to patients without HCV.

The Vaccines and Related Biological Products Advisory Committee's (VRBPAC) positive vote follows the committee’s review of the data from the biologics license application (BLA) for RBX2660.

This will include 3 trials to examine the therapy in different formulations in HIV studies.

Eravacycline is an antibiotic that has been touted for possible treatment of difficult-to-treat resistant (DTR) Gram-negative infections. But can it tackle carbapenem-resistant Acinetobacter baumannii (CRAB) infections?

The study authors identified four main approaches to antimicrobial stewardship programs after questionnaire and focus group discussions with ASP leaders.

The Paxlovid approval reaffirms the importance of pharmacists in fighting COVID-19.

As greenhouse gas emissions result in floods, heat waves, and more extreme weather events, people and pathogens are thrown closer together.

In 2020 alone, the COVID-19 pandemic may have caused an additional 10500 heart attacks, strokes, and other blood clot complications across England and Wales.

Here is a review of using this therapy in this patient population.

After positive top-line data from phase 3 trials for their meningococcal vaccine, MenABCWY, Pfizer intends to submit a Biologics License Application (BLA) to the FDA.